H 100

Drug Profile

H 100

Alternative Names: H-100™

Latest Information Update: 11 May 2016

Price : $50

At a glance

  • Originator Hybrid Medical
  • Class Anti-inflammatories; Antifibrotics
  • Mechanism of Action Fibroblast growth factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Peyronie's disease

Most Recent Events

  • 11 May 2016 Phase I development is ongoing in USA
  • 31 Dec 2013 Hybrid Medical completes a phase I trial in Peyronie's disease in USA (NCT02072018)
  • 30 Jun 2013 Phase-I clinical trials in Peyronie's disease in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top